journal
MENU ▼
Read by QxMD icon Read
search

Cardiovascular Therapeutics

journal
https://www.readbyqxmd.com/read/28643478/critical-role-of-tnf-inhibition-in-combination-therapy-for-elderly-mice-with-atherosclerosis
#1
Kyung-Yeon Park, Tae-Hwe Heo
We have previously shown that the combination of pravastatin and sarpogrelate is synergistically beneficial for atherosclerosis. In this study, we investigated whether the pravastatin-sarpogrelate combination was sufficient for treatment in an old mouse model of atherosclerosis or if additional intervention would be needed to address the newly included aging factor and its complex pathophysiological impact on the atherosclerogenic state. We added an anti-TNF biologic to the combination treatment cocktail because of the known pathologic roles of TNF in the aging process...
June 23, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28643448/post-conditioning-with-metformin-attenuates-apoptotic-events-in-cardiomyoblasts-associated-with-ischemic-reperfusion-injury
#2
Rajesh Ramachandran, Mini S
Ischemic post-conditioning is considered as a potent method to combat ischemic reperfusion injury than pre-conditioning since the latter is non predictive and risky. Rapid initiation of reperfusion with potent anti oxidant compound can be one of the most effective treatments to reduce the infract size and behavioural deficits as a result of ischemic insult. Apoptosis/Necrotic events undisputedly hold significant role in determining the fate of cardiomyocytes post ischemic injury but current studies are speculative regrading the role of post-conditioning in maintaining cellular homeostasis...
June 23, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28643420/impact-on-survival-of-warfarin-in-patients-with-pulmonary-arterial-hypertension-receiving-subcutaneous-treprostinil
#3
Mona Ascha, Xuan Zhou, Youlan Rao, Omar A Minai, Adriano R Tonelli
INTRODUCTION: Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk / benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS: We use observational long-term data on PAH patients treated with subcutaneous (SQ) treprostinil from a large open-label study. Patients were followed for up to four years. The use of warfarin and bleeding events were recorded...
June 23, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28636290/sulforaphane-protection-against-the-development-of-doxorubicin-induced-chronic-heart-failure-is-associated-with-nrf2-upregulation
#4
Yang Bai, Qiang Chen, Yun-Peng Sun, Xuan Wang, Li Lv, Li-Ping Zhang, Jin-Sha Liu, Song Zhao, Xiao-Lu Wang
Doxorubicin (DOX) is an anthracycline anti-tumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity, and even progresses to chronic heart failure (CHF). OBJECTIVE: This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS: Male Sprague Dawley rats who received treatment for six weeks were divided into four groups (n=30 per group): control, SFN, DOX, and DOX plus SFN group. RESULTS: Results revealed that DOX induced progressive cardiac damage as indicated by increased cardiac injury markers, cardiac inflammation, fibrosis and oxidative stress...
June 21, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28636184/pharmacokinetics-pharmacodynamics-of-bococizumab-a-monoclonal-antibody-to-pcsk9-after-single-subcutaneous-injection-at-3-sites-nct-02043301
#5
Ellen Q Wang, Anna Plotka, Joanne Salageanu, Catherine Sattler, Carla Yunis
AIM: To characterize the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), administered subcutaneously (s.c.) to the abdomen, thigh, or upper arm (NCT02043301). METHODS: Seventy-five adults with low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dL and not on background lipid-lowering therapy were randomized (1:1:1) to a single 150-mg s.c. dose of bococizumab administered to the abdomen, thigh, or upper arm...
June 21, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28599085/exploring-the-putative-role-of-trpv1-dependent-cgrp-release-in-remote-hind-preconditioning-induced-cardioprotection
#6
Puneet Kaur Randhawa, Amteshwar Singh Jaggi
Remote ischemic preconditioning (RIPC) is a phenomenon whereby transient non-lethal ischemia and reperfusion episodes confer protection against prolonged ischemia-reperfusion-induced injury. However, the underlying intracellular signaling has not been extensively explored. The present study aims to inspect the putative involvement of TRPV1 -dependent CGRP release in mediating remote hind limb preconditioning-induced cardioprotection. In the present study, remote hind limb preconditioning stimulus was delivered (4 consecutive episodes of 5 minutes of ischemia-reperfusion) using a blood pressure cuff tied at the inguinal level of the rat...
June 9, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28556504/effects-of-conjugated-linoleic-acid-supplementation-on-serum-c-reactive-protein-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#7
REVIEW
Mohsen Mazidi, Ehsan Karimi, Peyman Rezaie, Gordon A Ferns
AIM: To undertake a systematic review and meta-analysis of prospective studies to determine the effect of conjugated linoleic acids (CLAs) supplementation on serum C-reactive protein (CRP). METHOD: PubMed-Medline, Web of Science, Cochrane Database and Google Scholar databases were searched (up until May 2016) to identify prospective studies evaluating the impact of CLAs supplementation on serum CRP. Random effects models meta-analysis was used for quantitative data synthesis...
May 29, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28544636/visit-to-visit-systolic-blood-pressure-variability-predicts-treatment-related-adverse-event-of-hyponatremia-in-sprint
#8
Abhinav Goyal, Kenechukwu Mezue, Janani Rangaswami
Hypertension is a common condition and an important cardiovascular risk factor. SPRINT trial showed that the beneficial effects of targeting systolic blood pressure <120 mmHg were accompanied by more adverse events. De-identified SPRINT database was used for this analysis. All subjects in each group that achieved their respective target blood pressure (<120, intensive; <140, standard) were included. Only readings after reaching target blood pressure for the first time were included. Subjects that never reached target or had <2 readings upon reaching target were excluded...
May 25, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28520220/endothelial-damage-effects-of-circulating-microparticles-from-patients-with-stable-angina-is-reduced-by-aspirin-though-erk-p38-mapks-pathways
#9
Cheng Gong, Xue-Feng Shan, Xu-Lang Wang, Wei-Wei Dong, Zhe Li, D Xin-Hong Liu, Wei Zhang, Kun Xing, Feng-Jun Chang
INTRODUCTION: Platelet activation participate in the development of both coronary artery disease (CAD) and circulating microparticles (MPs). As a commonly used medicine for coronary heart disease, whether aspirin affects the function of MPs remains unclear. AIMS: This study was designed to test MPs from healthy subjects, stable angina (SA) patients before and after aspirin administration were obtained. MPs origins were tested by flow cytometry. Rat thoracic aortas were incubated with MPs (with or without aspirin) to determine the effects of MPs on expression of ERK1/2, JNKs and p38 MAPK...
May 18, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28489317/pharmacogenomics-of-angiotensin-receptor-neprilysin-inhibitor-and-its-long-term-side-effects
#10
REVIEW
Chayakrit Krittanawong, Takeshi Kitai
The development of the promising agent sacubitril/valsartan, known as an angiotensin receptor blocker-neprilysin inhibitor (ARNI), to improve heart failure (HF) management, may benefit morbidity, mortality, and readmission rates in patients with HF. The PARADIGM-HF trial demonstrated that the ARNI can reduce morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), while ongoing PARAMOUNT and PARAGON-HF trials determined whether the ARNI has morbidity and mortality benefits in patients with heart failure with preserved ejection fraction (HFpEF)...
May 10, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28467641/association-of-body-mass-index-with-mortality-in-chinese-patients-after-percutaneous-coronary-intervention-a-large-single-center-data
#11
Huanhuan Wang, Zhan Gao, Xueyan Zhao, Shubin Qiao, Yuejin Yang, Runlin Gao, Bo Xu, Jinqing Yuan
BACKGROUND: Although numerous studies to date have demonstrated a specific phenomenon called the "obesity paradox" in patients after percutaneous coronary intervention (PCI), studies performed in China thus far have consistently shown an absence of this phenomenon. HYPOTHESIS: "Obesity paradox" does exist in Chinese PCI patients. METHODS: 10,724 consecutive Chinese patients who had undergone PCI treatment at a single center from January 2013 to December 2013 were prospectively recruited...
May 3, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28459500/gender-related-differences-in-antiplatelet-treatment-patterns-and-outcome-insights-from-the-greekantiplatelet-grape-registry
#12
I Xanthopoulou, P Davlouros, S Deftereos, M Hamilos, G Sitafidis, I Kanakakis, M Vavouranakis, J Goudevenos, J Lekakis, D Alexopoulos
AIMS: Data on the clinical impact of gender in 'real life' acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS: In a prospective, observational, multicenter, cohort study 2047 patients were recruited into the GReekAntiPlatElet (GRAPE) Registry and were followed-up until 1 year for major adverse cardiovascular events (MACE, composite of death, non fatal myocardial infarction,urgent revascularization and stroke) and bleeding events [Bleeding Academic Research Consortium (BARC) classification]...
April 29, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28445625/the-use-of-an-occlusion-perfusion-catheter-to-deliver-paclitaxel-to-the-arterial-wall
#13
Marzieh K Atigh, Emily Turner, Uwe Christians, Saami K Yazdani
AIM: Non-stent drug delivery platforms have recently emerged as an alternative treatment of peripheral arterial disease. Perfusion catheters have the potential to directly deliver anti-proliferative agents to the medial arterial layer to prevent restenosis. The purpose of this study was to therefore determine the effectiveness of a perfusion catheter to deliver paclitaxel, a proven anti-proliferative agent, to combat restenosis. METHODS: A bench-top model was utilized to determine the varying parameters of a novel occlusion perfusion catheter to maximize paclitaxel delivery using pharmacokinetic evaluation and fluorescent microscopy...
April 26, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28444860/aspirin-responsiveness-changes-in-obese-patients-following-bariatric-surgery
#14
Nicholas B Norgard, Scott V Monte, Stanley F Fernandez, Qing Ma
Bariatric surgery has emerged as a promising treatment option for weight loss and to counter the metabolic consequences of obesity. Obesity has been linked to a hyperaggregable state, as well as a blunted response to aspirin. This pilot study assessed the hypothesis that bariatric surgery would lead to an improvement in aspirin-induced platelet inhibition and a reduction in platelet aggregability. METHODS: Fifteen patients scheduled to undergo bariatric surgery were administered two 7-day courses of aspirin 81 mg: the first course administered before surgery and the second was 3 months following surgery...
April 26, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28423237/assessment-of-vascular-response-to-bioss-lim-c-%C3%A2-stents-vs-orsiro-%C3%A2-stents-in-the-porcine-coronary-artery-model
#15
Jacek Bil, Robert J Gil, Tomasz Pawlowski, Krzysztof P Milewski
AIMS: The optimal treatment strategy for coronary bifurcation lesions is still unknown. The aim of the study was to assess applicability of the new cobalt-chromium version of the sirolimus-eluting dedicated bifurcation BiOSS(®) LIM C stent in comparison with regular sirolimus-eluting Orsiro(®)  stent in a porcine coronary model. METHODS: A total of 13 BiOSS(®) LIM C stents and 6 Orsiro(®) stents were implanted in normal non-atherosclerotic porcine straight coronary arteries of six animals using 1...
April 19, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28423234/pulmonary-vein-isolation-with%C3%A2-concomitant%C3%A2-renal-artery-denervation%C3%A2-is-associated-with-reduction-of-both-arterial-blood-pressure-and-atrial-fibrillation-burden-data-from-implantable-cardiac-monitor
#16
Alexander Romanov, Evgeny Pokushalov, Dmitry Ponomarev, Artem Strelnikov, Vitaliy Shabanov, Denis Losik, Alexander Karaskov, Jonathan S Steinberg
BACKGROUND: Renal artery denervation (RDN) has provided incremental atrial fibrillation (AF) suppression after pulmonary vein isolation (PVI) in patients with AF in the setting of drug-resistant hypertension. OBJECTIVE: To assess the relationship between changes of mean blood pressure (BP) and AF recurrences/AF burden after PVI combined with RDN. METHODS: All patients from two randomized studies with symptomatic paroxysmal AF and/or persistent AF and resistant hypertension who underwent PVI only (n=37) or PVI with RDN (n=39), and implantable cardiac monitor (ICM) implantation, were eligible for this study...
April 19, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28423233/ivabradine-versus-metoprolol-in-patients-with-acute-inferior-wall-myocardial-infarction-expanding-arena-for-ivabradine
#17
Rajendra K Go Khroo, K Priti, Bhanwar L Ranwa, Kamal Kishor, Devendra Bisht, Sajal Gupta
BACKGROUND: Atrioventricular (AV) blocks are of concern with the use of beta blockers in inferior wall myocardial infarction (MI). Ivabradine lowers heart rate with a lesser risk of AV blocks. OBJECTIVES: To compare ivabradine with metoprolol in acute inferior wall MI in terms of feasibility, tolerability and efficacy METHODS: It was a prospective double blind single centre randomized controlled study. Of 1032 patients with acute inferior wall MI, 468 eligible patients were randomized in 1:1 manner to ivabradine (group A) and metoprolol (group B)...
April 19, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28423226/rvx-208-a-novel-bet-protein-inhibitor-role-as-an-inducer-of-apo-a-i-hdl-and-beyond
#18
Gopal C Ghosh, Rajarshi Bhadra, Raktim K Ghosh, Kinjal Banerjee, Anjan Gupta
Low density cholesterol (LDL) has been the prime target of currently available lipid-lowering therapies although current research is expanding the focus beyond LDL lowering and has included high density cholesterol (HDL) also as the target. Bromo and extra-terminal (BET) proteins are implicated in the regulation of transcription of several regulatory genes and regulation of pro-inflammatory pathways. As atherosclerosis is an inflammatory pathway and studies showed that BET inhibition has a role in inhibiting inflammation, the concept of BET inhibition came in the field of atherosclerosis...
April 19, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28391633/comparisons-of-cardioprotective-efficacy-between-fibroblast-growth-factor-21-and-dipeptidyl-peptidase-4-inhibitor-in-pre-diabetic-rats
#19
Pongpan Tanajak, Piangkwan Sa-Nguanmoo, Nattayaporn Apaijai, Xiaojie Wang, Guang Liang, Xiaokun Li, Chao Jiang, Siriporn C Chattipakorn, Nipon Chattipakorn
AIMS: Comparative efficacy between fibroblast growth factor 21 (FGF21) and vildagliptin on metabolic regulation, cardiac mitochondrial function, heart rate variability (HRV) and left ventricular (LV) function is not known. We hypothesized that FGF21 and vildagliptin share a similar efficacy in improving these parameters in high-fat diet (HFD) induced obese-insulin resistant rats. METHODS: Twenty-four male Wistar rats were fed with either a normal diet (ND) or a HFD for 12 weeks...
April 9, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28371472/epigenetic-regulation-in-monocyte-macrophage-a-key-player-during-atherosclerosis
#20
Su-Jie Jia, Ke-Qin Gao, Ming Zhao
Atherosclerosis is a chronic inflammatory disease. Recently, a growing body of evidence emphasizes that the monocyte and macrophage differentiation and activation are key processes in the development of atherosclerosis. However, the regulatory mechanism that manipulates the function of monocyte and macrophage is still unclear. Recent years, epigenetic mechanisms have got a widely attention and bring us a new field of vision. More and more evidence shows that epigenetics weigh highly in atherosclerosis by regulating the function and differentiation states of monocyte and macrophage...
April 2, 2017: Cardiovascular Therapeutics
journal
journal
41804
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"